The association between Epstein-Barr virus (EBV) and breast carcinoma in Iranian women is uncertain. We examined EBV latent membrane protein-1 (LMP-1) antigen expression in breast carcinoma and its relationship with clinicopathologic parameters among a population of Iranian patients.
INTRODUCTION
Breast carcinoma is most common cause of cancer related death among woman world-wide. [1] According to official statistics from cancer registry, breast cancer is the most common type of cancer among Iranian women. [2] Although there are well-known risk factors associated Copyright: © 2014 Mohammadizadeh. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
with breast carcinoma including early age of menarche, late age of menopause, nulliparity and positive family history of breast cancer, these cannot explain many cases of breast cancer. [3] In recent years, certain viruses have been the focus of attention as potential risk factors for the development of breast cancer. Among viruses, Cytomegalovirus and Epstein-Barr virus (EBV) have been the subject of several studies in various parts of the world. The hypothesis of the presence of an association between EBV and breast cancer originates from some noteworthy observations. Incidence of breast cancer is high among men in Mediterranean countries, where EBV infection is endemic. Moreover, some EBV associated lymphomas have been reported in breast and there are striking morphological similarities between medullary carcinoma of breast and the well-known EBV associated nasopharyngeal carcinoma. [3, 4] Reports of concurrent nasopharyngeal carcinoma and breast carcinoma further strengthen this hypothesis. [5, 6] EBV is a gamma herpes virus. Infection typically occurs early in life and may show a lifelong persistence, usually without serious health consequences. The association between EBV infection and certain malignancies such as Burkitt lymphoma and nasopharyngeal carcinoma is well-documented. [7] Despite several studies concerned with the issue of EBV association with breast cancer, the findings are controversial. In a recent study published in 2012, thirty investigations regarding the association of EBV and breast cancer have been reviewed with special attention to the methodology of these studies, sample size and proportion of specimens reported as positive for EBV. This review shows that the published data do not justify a conclusion that EBV is etiologically associated with breast cancer. [8] According to controversial results, our purpose was to assess the presence of EBV in breast carcinoma from a series of Iranian patients. To the best of our knowledge, only one study regarding the etiologic role of EBV in breast carcinoma among Iranian women has been published in English literature. [9] The slides were then evaluated by two pathologists using two-headed light microscope.
MATERIALS AND METHODS

This
A well-documented EBV positive nasopharyngeal carcinoma was used as positive control. Nuclear staining with LMP-1 antibody irrespective of the intensity of staining and the percentage of the stained cells was considered as positive LMP-1 expression. Other data including age at the time of diagnosis, tumor size (greatest tumor dimension) and the status of axillary lymph node were obtained from the records available in the patients' documents.
T h e d a t a w e r e a n a l y z e d u s i n g t h e S P S S software (version 16, Chicago) for windows.
McNemar test was used to determine the association between EBV and breast carcinoma. The relationship between EBV and tumor grade was determined by Mann-Whitney test. Independent t-test was used to determine the relationship between EBV and age, tumor size and lymph node status. P < 0.05 was considered as statistically significant.
RESULTS
In this study, 80 paraffin blocks of breast carcinoma were evaluated. Cancer characteristics are presented in Table 1 . Six (7.5%) out of 80 carcinoma samples showed positive immunoreactivity for LMP-1 [ Figure 1 ]. LMP-1 expression was not seen in any of the normal breast tissue samples adjacent to carcinoma. Mc Nemar test showed a statistically significant association between EBV and invasive breast carcinoma (P = 0.03).
Mann-Whitney test showed no statistically significant relationship between LMP-1 expression as the marker of EBV presence and tumor grade in invasive ductal carcinomas (P = 0.847) [ Table 2 ].
Out of 80 samples, 77 were invasive ductal carcinoma. The remainder included one lobular carcinoma, one mucinous carcinoma and one medullary carcinoma. All the LMP-1 positive specimens belonged to invasive ductal carcinoma subtype. Since the numbers of carcinoma subtypes other than invasive ductal carcinoma were too small, study of relationship between LMP-1 expression as the marker of EBV presence and tumor type could not yield valid results [ Table 3 ].
Independent t-test failed to show any statistically significant relationship between LMP-1 expression Table 4 ].
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The relationship between LMP-1 expression and lymph node status was also determined by Mann-Whitney test. This test confirmed the lack of a statistically significant relationship between LMP-1 expression and lymph node status (P = 0.49).
DISCUSSION
Establishing an etiologic role for certain viruses in the development of breast carcinoma may have impacts on prevention and early detection of the breast cancer in infected and at risk populations in future.
In this study, we have investigated the expression of LMP-1 antigen of EBV in tumoral cells of invasive breast carcinoma and adjacent normal breast tissue using the IHC technique. We found LMP-1 expression in breast carcinoma cells in 7.5% of the studied samples, while none of the normal breast tissue samples adjacent to carcinoma showed LMP-1 expression. These results showed a statistically significant association between EBV and invasive breast carcinoma. Association between EBV and breast cancer has been reported in several studies from different countries. Mazouni et al. from France have reported the presence of EBV deoxyribonucleic acid (DNA) in 33.2% of the studied cases using the real-time quantitative polymerase chain reaction (PCR) technique. [10] Joshi et al. from India studied EBV nuclear antigen-1 (EBNA-1) in breast cancer tissue and benign breast diseases in rural Indian women. In both groups, they also measured anti-EBNA-1 IgG antibodies in sera of these patients. IHC for EBNA-1 was positive in 54.9% of breast cancer cases. No IHC positivity was detected in the samples from the control group with benign breast diseases. EBNA-1 IgG antibody levels were also significantly higher in breast cancer group compared to the control group. [3] Fawzy et al. from Egypt compared EBNA-1 expression by immunostaining and PCR in samples from breast carcinoma and fibrocystic disease. IHC positivity of EBNA-1 was found in 25% of breast cancer specimens. Of these, 80% were also positive for EBNA-1 DNA in PCR. Fibrocystic disease specimens were negative by both techniques. [11] Preciado et al. from Argentina used both IHC and PCR techniques and found EBNA-1 expression in 35% of breast carcinoma samples. None of the control samples with benign breast diseases were EBNA-1 positive. [12] In the study of Labrecque et al. from United Kingdom 21% of the breast carcinoma cases were positive for EBV DNA by PCR technique. [13] Glenn et al. from Australia identified EBV sequences by PCR technique in 68% of invasive breast cancer specimens. [14] Zekri et al. did a study on breast carcinoma specimens and normal breast tissue of Egyptian and Iraqi women. They used IHC, in situ hybridization and PCR techniques and detected EBV in 45% and 28% of Egyptian and Iraqi women with breast carcinoma, respectively. Control group was negative for EBV. [15] Hachana et al. used specific PCR assays and found EBV DNA in 27% of breast carcinoma cases in Tunisia. [16] Another study from Tunisia by Trabelsi et al. used IHC and in situ hybridization techniques and detected EBV virus in 16.6% of medullary carcinomas and 11% of high grade invasive ductal carcinomas with lymphoid stroma. [17] He et al. from China investigated serum immunoglobulin A (IgA) and IgG levels against EBV viral capsid antigen (VCA) and EBNA-1 in women with breast carcinoma and controls in a high incidence area of nasopharyngeal carcinoma. Their results showed a significant association between VCA IgA levels and increased risk of breast cancer. IgG variables were not related to breast carcinoma. [18] Huo et al. reviewed 24 studies and 1535 cases and found that 29.32% of the patients with breast cancer were infected with EBV. They reported the highest prevalence of EBV in Asia and the lowest prevalence of the virus in USA. [19] Variable prevalence of EBV association with breast carcinoma in these studies may be attributable to several factors including the sample size and methodology. PCR and in situ hybridization techniques are certainly more accurate compared with IHC technique. Moreover, proteins of EBV targeted for study have not been the same in all of these investigations. Another important factor seems to be the impact of the prevalence of EBV infection since the prevalence of the infection is different in various parts of the world.
Although most studies have suggested a possible association between EBV and breast carcinoma, there are studies that have failed to find such a relationship. Kadivar et al. from Iran studied EBV presence in breast carcinoma and benign breast diseases using IHC and PCR techniques. Studied EBV markers were negative in all breast cancer and control specimens. [9] Perrigoue et al. from USA used real-time quantitative PCR and reported lack of association between EBV and breast carcinoma. [20] According to the finding of the study of Baltzell et al. from USA who used in situ molecular methods of viral detection, EBV is unlikely to have a causative role in most types of breast carcinoma. [21] We found no statistically significant relationship between LMP-1 expression on one hand and age, tumor size, tumor grade and lymph node status on the other. Since tumor subtypes other than invasive ductal carcinoma were very small in number in our study, we could not obtain statistically valid results concerning the relationship between LMP-1 expression and tumor subtype in invasive breast carcinomas. The issue of relationship between EBV expression and clinicopathological prognostic determinants of breast carcinoma has been studied in some previous studies as well. Preciado et al. showed no significant relationship between EBV expression and worse clinicopathological determinants. [12] Labrecque et al. found no statistical association between EBV expression and tumor subtype. [13] Hachana et al. have reported the absence of any significant correlation between EBV expression and patient age, tumor grade, tumor size and lymph node status. However, they found a statistically significant relationship between EBV expression and estrogen receptor negativity. [16] Chu et al. also found that identification of EBV was not associated with tumor size, tumor grade and nodal status. [22] On the other hand, some of the studies have reported the presence of significant association between EBV expression and some of the clinicopathological prognostic parameters of breast carcinoma. Mazouni et al. have found more aggressive features in breast cancers with EBV expression including more frequent estrogen receptor negativity and high histological grade. [10] According to results from the study of Fawzy et al., EBV-DNA positive breast cancers were associated with more than three lymph nodes involvement. [11] Glenn et al. reported that the presence of EBV in breast carcinoma is associated with young age of the patient at diagnosis. [14] Regarding tumor subtype, the strongest association might be present between lobular carcinoma and EBV infection. [19] Since interleukin-10 and interferon-γ (INF-γ) play a critical role in the host responsiveness to EBV infection, their genetic variations may modify the association between EBV infection and the risk of breast carcinoma. Such a role has especially been suggested for genetic variations in INF-γ. [23] Controversial results from the studies on the issue of EBV association with breast carcinoma emphasize on the need for further studies in this field to achieve more valid results. Serological studies to identify life-time EBV exposure in new cases of breast cancer and simultaneous study of EBV markers in breast carcinoma tissue of seropositive patients may further help us to clarify the complicated issue of association between EBV and breast cancer.
CONCLUSION
The results of this study suggest a potential causative role for EBV in some cases of Iranian women with invasive breast carcinoma. However, EBV expression does not seem to be correlated with the major clinicopathological prognostic determinants of the breast cancer.
